Editorial Board

The publisher would like to thank the members of the Life Sciences Intellectual Property Review editorial board:

MaryAnne Armstrong is a partner at Birch, Stewart, Kolasch & Birch, LLP. She has practiced in the IP field since 1995, working with both large and small companies and universities, for the preparation and prosecution of patent applications in the fields of immunology, pharmaceutical chemistry, biotechnology, organic chemistry, assay and drug screening systems, medical devices and plant patents. She is experienced in post-grant procedures, including inter-partes reexamination and interference practices.

Trevor Cook is a partner at Wilmer Cutler Pickering Hale and Dorr LLP in New York with more than 35 years of experience in IP litigation. While his main area of focus is patent and other IP litigation and advice, he is also active in the area of life sciences administrative law. He is president of the UK Group of the International Association for the Protection of Intellectual Property and chairman of the British Copyright Council. He is also on the World Intellectual Property Organization list of arbitrators.

Gabriel Di Blasi is a Brazilian patent attorney, lawyer and partner of Di Blasi, Parente & Associados with offices in Rio de Janeiro and São Paulo, which specialises in intellectual property issues. He has a technical background in industrial engineering and also has expertise in patent prosecution and litigation. His core practice areas include domestic and international patents, designs, plant variety rights, tech transfer, regulatory, and trade secrets matters.

Paul England, of Taylor Wessing LLP, specialises in patent litigation, particularly in the life sciences sector, and has advised in a number of high-profile disputes. He is now the knowledge management lawyer in Taylor Wessing's Patents Group. Before becoming a lawyer, Paul was a scientist and has a doctorate in biochemistry and molecular biology from the University of Oxford. He also has experience as a bench chemist for a GSK predecessor company. Paul publishes and speaks on patent related matters regularly, is the author of a book on expert privilege, and the consulting editor of a further book on intellectual property in the life sciences.

Dr Janis K Fraser is a principal at Fish & Richardson PC, a premier IP firm with offices throughout the US and in Munich. Janis holds a PhD in biochemistry from Massachusetts Institute of Technology and a JD from Harvard Law School. For over 20 years she has represented large and small biotechnology and pharmaceutical companies, academic institutions, and venture capital organizations, assisting her clients in securing and defending their patents at the US Patent and Trademark Office and in formulating strategies related to IP and licensing worldwide.

Gunars Gaikis is senior counsel at Norton Rose Fulbright based in Toronto. He is one of Canada's most experienced life sciences intellectual property litigators, with more than 30 years of experience in the highly technical field of pharmaceutical patent, trademark and related litigation. He has appeared as lead counsel in numerous intellectual property cases before the Ontario and federal courts, as well as the Supreme Court of Canada.

Dr Penny Gilbert is a partner of Powell Gilbert LLP, a specialist IP law firm based in London. She is a solicitor advocate and a qualified mediator. Penny has a degree in biochemistry and DPhil in molecular biology from Oxford University. She specialises in patent litigation, particularly in the life sciences, and represents clients before the UK Patents Courts, including acting in the first patent case to be heard by the UK Supreme Court (HGS v Eli Lilly), and in proceedings before the CJEU.

Andrew Jenner is director of IP, innovation and trade at the International Federation of Pharmaceutical Manufacturers and Associations. He joined IFPMA in late 2009. Prior to joining IFPMA, he held a number of policy roles in the UK Government including the principal UN/WTO negotiator on IP, trade & development for the UK Intellectual Property Office. He also led the UK Government’s IP crime strategy. Before joining government, he worked in the automotive industry as a quality control advisor.

Ashwin Julka is the managing partner of Remfry & Sagar. His professional experiences span nearly two decades and cover the full spectrum of IP rights. An active member of several IP organizations including INTA, APAA, AIPPI, ITMA and PTMG, he is well recognised on the international circuit. His qualifications include bachelors degrees in economics and law, both from the University of Delhi.

Lars Kellberg, corporate vice-president and chief patent counsel at Novo Nordisk A/S. In this position he is globally responsible for Novo Nordisk’s patent operation. He is based in the corporate headquarters of Novo Nordisk in Copenhagen, Denmark. Prior to joining Novo Nordisk, Lars worked as an associate of a Danish intellectual property law firm, representing European and American clients in patent matters. Prior to his position in private practice, Lars was pursuing post-graduate academic research at the Department of Chemistry, University Of Aarhus.

Judith Kim is a partner at Rubin and Rudman. She counsels entities around the world on patent portfolio strategy and long-term corporate development. Her practice involves the preparation of patent applications and their prosecution and appeals worldwide, contesting proceedings before the US Patent and Trademark Office, and management of foreign oppositions to protect inventions and maximise market share. For nearly 20 years, Ms Kim has counselled entities in the pharmaceuticals, biotechnology, immunology, biofuel, food products, and nutraceuticals fields.

Dr Simon Kremer is a partner at Mewburn Ellis LLP. He has over 20 years’ experience helping clients with their intellectual property needs. Simon has a degree and PhD in biochemistry from the University of Bristol and started his career in a UK Government intellectual property rights department in 1992, where he gained experience in prosecution and licensing of many types of IPR. He joined Mewburn Ellis in 1997 and now deals mainly with patent drafting, international prosecution, opposition and appeal before the EPO, and various types of due diligence work, in a wide range of technical fields.

Nathalie Moll, director general at the European Federation of Pharmaceutical Industries and Associations, started working in the biotechnology and food policy area for the European Crop Protection Association in Brussels, then moved to Rome to work for Dompé Farmaceutici S.p.A and the Italian National Biotech Association Assobiotec where she dealt with the implementation of European biotech legislation. In the course of her career, Nathalie has focused on improving awareness of the importance and benefits of biotechnology for society and has worked, together with the industry, regulators and stakeholders, towards developing a more supportive legislative framework for the industry and related sectors.

Caroline Pallard has worked as a European and Dutch patent attorney at Nederlandsch Octrooibureau since 2006. Her technical background is biotechnology, molecular biology, biochemistry, haematology and microbiology. Additionally, she has expertise in food ingredient-based inventions. She works for universities, small start-ups as well as international food concerns. Pallard holds a PhD in haematology and molecular biology, and undertook two years of postdoctoral research related to immunology and molecular biology. She worked in the patent department of an international concern for eight years before joining NOB.

Jason Rutt is a patent attorney at Boult Wade Tennant. He has previously worked at Pfizer, where he was head of the UK patent department. While at Pfizer, he supported the company's R&D function, human pharmaceuticals division, animal health division and generics medicine business, and worked closely with the commercial and litigation teams. He has experience of working with the EPO in all areas from prosecution, opposition, appeal and oral proceedings to post-grant amendment.

Jose R. Trigueros is a partner at Leyva Montenegro Trigueros Abogados SC. He graduated at the Universidad de las Americas, AC in 2006 and continued with graduate studies in IP at the Illustrious and National College of Law, Mexico. He completed a Masters in IP at the University of Torino and a Masters in corporate law at Mexico’s Panamerican University. In 2011, Trigueros was appointed professor of economic law and commercial contracts at the Instituto Tecnologico de Estudios Superiores de Monterrey, Santa Fe campus.

Dr Joachim Wachenfeld is a partner in the biotech department of the IP boutique Vossius & Partner in Munich. Originally trained in immunology, he has a long standing experience in all fields of biotech. Presently, he heads a group of five patent attorneys. His group widely covers prosecution, opposition and nullity proceedings as well as FTO analyses. Dr Wachenfeld has been a member of international litigation teams and served as an advisor to the EU commission in 1998. He has given numerous lectures on IP-related issues in Germany and abroad.

Jane Wainwright, partner at Potter Clarkson LLP, is a UK and European patent attorney specialising in the life sciences. She has been providing commercially strategic advice to industrial and academic clients on patents and oppositions in the life sciences field for many years, and has spoken on European patent practice at various international conferences.

Dr Franz-Josef Zimmer is a patent attorney at specialist IP firm Grünecker in Munich. Zimmer has a background in biochemistry and immunogenetics, and practices in the prosecution and enforcement of patents in the life sciences field. He has represented clients including universities, start-ups and larger companies before the German and European Patent Office, and is a member of the American Intellectual Property Law Association, German Association for the Protection of Intellectual Property and the International Federation of Intellectual Property Attorneys.